Oh Young Bang | Neuroscience | Best Researcher Award

Posted on by Forensic Scientist

Prof. Oh Young Bang | Neuroscience | Best Researcher Award

SAMSUNG MEDICAL CENTER | SOUTH KOREA

Prof. Oh Young Bang is a renowned neurologist and biomedical researcher, currently serving as a Professor in the Department of Neurology at Samsung Medical Center, affiliated with Sungkyunkwan University School of Medicine, Seoul, Korea. He also holds a professorship at the Samsung Advanced Institute for Health Sciences and Technology. In addition to his academic roles, he is the CEO of S&E Bio, a pioneering biotech company focused on stem cell-derived exosome therapies targeting incurable diseases. His contributions have significantly advanced both the clinical and translational neuroscience domains.

Professional profile👤

Google Scholar

ORCID

Strengths for the Awards✨

Professor Oh Young Bang stands as a global leader in the field of neurology, particularly in stroke research, neuroimaging, and stem cell-derived exosome therapy. His current roles—Professor at Samsung Medical Center, Sungkyunkwan University, and CEO of S&E Bio—showcase his academic and translational research excellence. His groundbreaking work bridges the gap between basic science and real-world clinical solutions, with a strong focus on biomarkers, risk factors, and novel therapies for incurable neurological diseases.

Bang’s publication record is exceptionally strong, with over 300 peer-reviewed SCI/SCIE papers, numerous book chapters, and participation in international multicenter clinical trials. His ability to move seamlessly from preclinical models to human trials emphasizes translational impact. His work on mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) has gained global recognition, notably for enhancing neuroplasticity post-stroke and showing scalable production methods.

Moreover, his editorial contributions to prestigious journals such as Stroke, J Stroke, and Cerebrovascular Disease, along with being Editor-in-Chief of Precision and Future Medicine, underline his thought leadership in the scientific community. The 30 patents he holds are a testament to his innovation-driven mindset and industry-aligned contributions.

🎓 Education

While specific degrees and institutions are not listed in the provided data, it is evident that Professor Bang’s academic foundation is firmly rooted in neurology and neuroscience, having led to his dual professorships and executive role in biotechnology. His advanced training has equipped him to bridge clinical neurology with innovative biotech applications.

💼 Experience

Professor Bang has built an illustrious career with extensive experience in clinical neurology, stroke research, and regenerative medicine. He actively leads preclinical and clinical stroke programs, emphasizing neuroimaging, biomarkers, risk factor analysis, and stem cell therapy. With a prolific output of over 300 SCI/SCIE-indexed articles, numerous book chapters, and 30 patents, he has played a pivotal role in global research and innovation. His leadership in international clinical trials and his contributions as a keynote speaker at global neurology and biotechnology conferences underscore his global impact.

🔬 Research Interests On Neuroscience

Professor Bang’s research focuses on stroke mechanisms, neuroimaging techniques, stem cell therapy, and biomarkers of neurological diseases. A notable aspect of his work includes advancing mesenchymal stem cell (MSC) therapy through extracellular vesicles, as well as developing scalable production methods for clinical applications. His research also investigates cancer-related thrombosis, arterial remodeling, and the neurovascular interface, making him a thought leader in translational neuroscience.

🏆 Awards & Editorial Roles

Though specific honors are not detailed, Professor Bang’s reputation is validated by his leadership roles in multiple top-tier journals. He served on the editorial boards of:

  • Stroke (2010–2015)

  • Journal of Stroke (since 2013)

  • Journal of Clinical Neurology (2006–2014)

  • Cerebrovascular Disease (2016–2019)
    Additionally, he was Editor-in-Chief of Precision and Future Medicine (2018–2022). His selection to these prestigious roles highlights his scientific influence and recognition in neurology and biomedical science.

📚 Selected Publications

  • Randomized assessment of rapid endovascular treatment of ischemic stroke
    Authors: M Goyal, AM Demchuk, BK Menon, M Eesa, JL Rempel, J Thornton, et al.
    Year: 2015
    Citations: 7,247

  • Autologous mesenchymal stem cell transplantation in stroke patients
    Authors: OY Bang, JS Lee, PH Lee, G Lee
    Year: 2005
    Citations: 1,489

  • A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke
    Authors: JS Lee, JM Hong, GJ Moon, PH Lee, YH Ahn, OY Bang
    Year: 2010
    Citations: 941

  • Collateral flow predicts response to endovascular therapy for acute ischemic stroke
    Authors: OY Bang, JL Saver, SJ Kim, GM Kim, CS Chung, B Ovbiagele, KH Lee, et al.
    Year: 2011
    Citations: 660

  • Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial
    Authors: MD Hill, M Goyal, BK Menon, RG Nogueira, RA McTaggart, AM Demchuk, et al.
    Year: 2020
    Citations: 609

  • Longitudinal changes of resting-state functional connectivity during motor recovery after stroke
    Authors: C Park, WH Chang, SH Ohn, ST Kim, OY Bang, A Pascual-Leone, YH Kim
    Year: 2011
    Citations: 567

  • Impact of collateral flow on tissue fate in acute ischaemic stroke
    Authors: OY Bang, JL Saver, BH Buck, JR Alger, S Starkman, B Ovbiagele, D Kim, et al.
    Year: 2008
    Citations: 479

  • Stroke statistics in Korea: part I. Epidemiology and risk factors
    Authors: KS Hong, OY Bang, DW Kang, KH Yu, HJ Bae, JS Lee, JH Heo, SU Kwon, et al.
    Year: 2013
    Citations: 442

  • Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis
    Authors: BCV Campbell, CBLM Majoie, GW Albers, BK Menon, N Yassi, G Sharma, et al.
    Year: 2019
    Citations: 407

  • Early neutrophilia is associated with volume of ischemic tissue in acute stroke
    Authors: BH Buck, DS Liebeskind, JL Saver, OY Bang, SW Yun, S Starkman, LK Ali, et al.
    Year: 2008
    Citations: 404

  • Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data
    Authors: L San Román, BK Menon, J Blasco, M Hernández-Pérez, A Dávalos, et al.
    Year: 2018
    Citations: 397

  • Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke
    Authors: OY Bang, JL Saver, SJ Kim, GM Kim, CS Chung, B Ovbiagele, KH Lee, et al.
    Year: 2011
    Citations: 364

  • The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy
    Authors: PH Lee, G Lee, HJ Park, OY Bang, IS Joo, K Huh
    Year: 2006
    Citations: 311

  • Collateral circulation in ischemic stroke: assessment tools and therapeutic strategies
    Authors: OY Bang, M Goyal, DS Liebeskind
    Year: 2015
    Citations: 305

🧾 Conclusion

Professor Oh Young Bang epitomizes excellence in translational neurology through his pioneering work in stroke research, neuroimaging, and stem cell-derived therapies. With a rare blend of academic leadership, clinical innovation, and industrial entrepreneurship, he represents a powerful force in the pursuit of solutions for some of medicine’s most intractable neurological challenges. His distinguished publications, editorial appointments, and patent portfolio collectively highlight his candidacy as a most deserving recipient of the Best Researcher Award.

Qingbao Guo | Neuroscience | Outstanding Scientist Award

Posted on by Forensic Scientist

Prof. Qingbao Guo | Neuroscience | Outstanding Scientist Award

Xi’an No.9 Hospital | China

Prof. Qingbao Guo is a highly accomplished Associate Chief Physician in the Department of Neurosurgery at the Second Affiliated Hospital of the Air Force Medical University (formerly Tangdu Hospital), China. He specializes in cerebrovascular disorders, brain tumors, and functional neurosurgery, and is recognized for his excellence in the diagnosis and treatment of moyamoya disease and other complex neurological conditions.

Professional profile👤

ORCID

Scopus

Strengths for the Awards✨

  1. Extensive Clinical Experience:

    • Over 20 years of progressive clinical practice in neurosurgery, including leadership as Associate Chief Physician at a top-tier military hospital.

    • Strong surgical expertise in cerebrovascular diseases, brain tumors, and functional neurosurgery, which are critical areas in modern neurosurgical practice.

  2. Academic Qualifications & Research:

    • A recent Ph.D. in Neurosurgery (2021–2024) focused on moyamoya disease (MMD)—a rare but significant cerebrovascular disorder.

    • Earlier Master’s-level research on peripheral vascular diseases, showing continuity in vascular-focused research.

    • Mentorship under established experts (Professors Lian Duan and Yanzheng He), enhancing academic rigor.

  3. Contribution to National Defense Health System:

    • His long-term service in military medical institutions (Air Force Medical University) underscores contributions to military medicine, a high-impact field with national importance.

  4. Interdisciplinary Relevance:

    • His work bridges clinical practice and surgical innovation, especially in the surgical management of complex neurological diseases, offering translational value to both academic and applied medicine.

🎓 Education

Prof. Qingbao Guo began his academic journey with a Bachelor’s degree in Clinical Medicine from Yan’an University (1999–2004). He furthered his specialization with a Master’s degree in Surgery (2008–2011) from Southwest Medical University, under the supervision of Prof. Yanzheng He, where he focused on clinical approaches to peripheral vascular diseases. Most recently, he earned his Ph.D. in Neurosurgery (2021–2024) from the Chinese PLA Medical School, mentored by Prof. Lian Duan, with research concentrating on the pathogenesis and surgical management of moyamoya disease.

💼 Professional Experience

Prof. Qingbao Guo has an extensive and progressive professional background in neurosurgery. He is currently serving as an Associate Chief Physician at Tangdu Hospital since September 2012, where he has amassed advanced surgical experience in managing brain tumors, vascular pathologies, and functional neurosurgical disorders. Prior to this, he was an Attending Physician at the First Affiliated Hospital of Southwest Medical University (July 2011 – August 2012), where he handled numerous vascular cases. His medical career began as a Resident Physician at Shaanxi Sengong Hospital (July 2004 – August 2008).

🔬 Research Interests On Neuroscience

Prof. Qingbao Guo’s research focuses on the pathophysiology and surgical treatment of cerebrovascular diseases, particularly moyamoya disease, a rare but serious condition affecting intracranial arteries. He is also interested in neuro-oncology, vascular neurosurgery, and advancements in functional neurosurgical procedures, with a vision to bridge translational neuroscience and surgical innovation.

🏆 Awards & Nominations

Prof. Qingbao Guo has been acknowledged for his clinical excellence and academic contribution through multiple hospital-level and regional honors. He is a nominee for the [Insert Award Name Here, e.g., “Outstanding Neurosurgeon Researcher Award 2025”] in recognition of his pioneering work in moyamoya disease surgical treatment and his consistent commitment to patient-centered research and education.

📚 Publications

🔬 Genetic Associations and Polymorphisms

  1. MTHFR Polymorphism and EDAS-induced Collateral Formation

    • [DOI: 10.3171/2024.1.JNS232121]
      Highlights the genetic influence (MTHFR) on surgical angiogenesis success post-EDAS in MMD patients.

  2. RNF213 p.R4810K Variant and Unfavorable Outcomes in Pediatric EDAS

    • [DOI: 10.1155/2024/1844190]
      Strong linkage of the RNF213 mutation with poor long-term outcomes, particularly relevant in East Asian populations.

🧪 Biomarker and Multi-Omics Studies

  1. Proteomic & Metabolomic Profiles in Pediatric MMD

    • [DOI: 10.2147/JIR.S471538]
      Identifies core disrupted pathways, potentially pointing toward new diagnostic or therapeutic targets.

  2. Complement C3 Expression & Postoperative Vasculopathy

    • [DOI: 10.2147/JIR.S451538]
      Suggests inflammatory markers like C3 as predictors of vascular changes post-intervention.

🧠 Neuroimaging and Risk Stratification

  1. MRI Vessel Wall Enhancement and MMD Outcomes

    • [DOI: 10.1007/S00330-023-10535-0]
      High-resolution MRI features were linked to clinical risk, potentially informing preoperative planning.

  2. Nomograms for Predicting Rebleeding and Outcomes

    • [DOI: 10.3171/2024.2.JNS232744]
      Well-validated clinical tools that integrate genetics and clinical features for long-term prognosis.

🧬 Pathophysiology and Comorbid Disease Connections

  1. Transcriptomics in MMD and SLE Crosstalk

    • [DOI: 10.3389/FIMMU.2024.1456392]
      A novel systems biology approach to uncover common pathways between MMD and autoimmune diseases like SLE.

  2. ZEB2 and Brain Microvascular Dysfunction Post-ICH

    • [DOI: 10.1080/15384101.2021.1959702]
      Delves into molecular mechanisms of endothelial dysfunction, bridging stroke and hemorrhage pathology.

📉 Risk Factors in Pediatric and Elderly Cohorts

  1. Preoperative Infarction & Pediatric Risk Factors

    • [DOI: 10.1007/S12975-023-01167-Z]
      Targeted focus on predictive markers in vulnerable pediatric populations.

  2. Outcomes in Elderly Post-Conservative vs. EDAS Treatment

  • [DOI: 10.3171/2023.7.JNS231060]
    Offers insights into age-specific management strategies and long-term care plans.

🔚 Conclusion

Prof. Qingbao Guo stands out as a dedicated neurosurgeon, educator, and researcher, committed to transforming patient outcomes through clinical expertise and scientific inquiry. His extensive training, hands-on experience, and impactful research make him a compelling candidate for any award celebrating excellence in medical and surgical innovation.

Chengqun Wei | Neuroscience | Best Researcher Award

Posted on by Forensic Scientist

Mr. Chengqun Wei | Neuroscience | Best Researcher Award

Associate Chief Physician | Huaian Hospital of Huaian city (Huaian Cancer Hospital) | China

Dr. Chengqun Wei is the Director of the Neurology Department and an Associate Senior Physician at Huaian Hospital of Huaian City. With a medical doctorate and a specialization in neurology, he has accumulated extensive expertise in geriatric neurology. Since beginning his medical career in 2012, Dr. Wei has dedicated over seven years to the treatment of acute cerebrovascular diseases, neurological infections, and demyelinating disorders. His vast clinical experience also includes managing elderly patients with comorbidities such as hypertension, diabetes, and cardiovascular diseases.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Medical Expertise: With a Ph.D. in Neurology and over a decade of clinical experience, Dr. Wei has demonstrated profound knowledge in geriatric neurology, cerebrovascular diseases, and neurological infections. His ability to manage complex neurological conditions in elderly patients is highly commendable.

✅ Research Contributions: Dr. Wei has authored 7 SCI-indexed publications, indicating a strong research output. Additionally, his involvement in multiple provincial-level research projects as a principal investigator or key participant highlights his active role in advancing medical knowledge.

✅ Technical Proficiency: His expertise in network pharmacology, bioinformatics analysis, and web data mining showcases his ability to integrate computational tools with medical research, a valuable asset in modern biomedical sciences.

✅ Leadership & Experience: Holding senior positions such as Associate Chief Physician and Director of Neurology, Dr. Wei has both clinical and research leadership experience, reinforcing his credentials as a top researcher.

🎓 Education

  • 🎓 2004.09-2009.06 – Xinxiang Medical University – Clinical Medicine (BD)
  • 🎓 2009.09-2012.06 – Harbin Medical University – Neurology (MD)
  • 🎓 2020.09-2023.06 – Harbin Medical University – Neurology (PhD)

💼 Experience

  • 2012.07-2015.05 – Resident Physician, Heilongjiang Provincial Hospital
  • 2015.05-2021.08 – Attending Physician, Heilongjiang Provincial Hospital
  • 2021.09-2024.03 – Associate Chief Physician, Heilongjiang Provincial Hospital
  • 2024.03-Present – Associate Chief Physician, Huaian Hospital of Huaian City

🔬 Research Interests On Neuroscience

Dr. Wei’s research focuses on network pharmacology, bioinformatics analysis, and web data mining for scientific research. His work contributes to advancements in understanding neurological diseases, particularly in geriatric populations. He is proficient in analyzing large-scale medical data and has authored multiple research papers in high-impact journals.

🏆 Awards

  • 🌟 Principal investigator or key participant in multiple provincial-level research projects.
  • 🌟 Recognized for excellence in neurology research and contributions to geriatric neurological care.

📚 Publications

  • Title: Single cell analysis reveals the roles and regulatory mechanisms of type-I interferons in Parkinson’s disease
  • Authors: Quan P., Li X., Si Y., Yang F., Yao L., and others
  • Publication Year: 2024
  • Journal: Cell Communication and Signaling
  • Citations: 4

🔚 Conclusion

Dr. Chengqun Wei is a highly skilled neurologist with a strong academic background and clinical expertise in geriatric neurology. His contributions to research, particularly in bioinformatics and pharmacology, have positioned him as a key figure in neurological studies. His dedication to patient care and medical advancements continues to make a significant impact in the field of neurology.